Volker Kunzmann

Comprehensive Cancer Center Mainfranken — Germany

Medicine · Health Sciences

49h-index11.1kcitations237works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(69), Cancer Genomics and Diagnostics(57), Colorectal Cancer Treatments and Studies(30), Gastric Cancer Management and Outcomes(28), Acute Myeloid Leukemia Research(24)

Publications236 total

2247P Growth differentiation factor 15 (GDF-15) in localized, non-metastatic pancreatic cancer treated with multiagent induction chemotherapy: A biomarker analysis from the randomized phase II NEOLAP-1 trial (AIO-PAK-0113)
Annals of Oncology·2025
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer
JCO Precision Oncology·2025· 1 citedOpen Access
Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance
Cellular Oncology·2025· 2 citedOpen Access
Five-year outcomes of perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (the NEONAX trial): A randomized phase II trial of the AIO pancreatic cancer group.
Journal of Clinical Oncology·2025
Precision oncology – Guideline of the Austrian, German and Swiss Societies for hematology and medical oncology
European Journal of Cancer·2025· 3 citedOpen Access
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition
Frontiers in Oncology·2025· 1 citedOpen Access
Minimally invasive determination of pancreatic ductal adenocarcinoma ( <scp>PDAC</scp> ) subtype by means of circulating cell‐free <scp>RNA</scp>
Molecular Oncology·2024· 3 citedOpen Access
1510P Exploration of circulating free bacterial DNA as a biomarker for therapy response in metastatic and locally advanced pancreatic cancer patients treated with systemic chemotherapy
Annals of Oncology·2024· 1 cited
Corrigendum to “Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)”
ESMO Open·2024· 1 citedOpen Access
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
˜The œLancet. Gastroenterology & hepatology·2024· 5 cited
Author response for "Minimally invasive determination of pancreatic ductal adenocarcinoma (&lt;scp&gt;PDAC&lt;/scp&gt;) subtype by means of circulating cell‐free &lt;scp&gt;RNA&lt;/scp&gt;"
2024
Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch
npj Precision Oncology·2024· 3 citedOpen Access
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
Journal of Cancer Research and Clinical Oncology·2024· 3 citedOpen Access
Author response for "Minimally invasive determination of pancreatic ductal adenocarcinoma (&lt;scp&gt;PDAC&lt;/scp&gt;) subtype by means of circulating cell‐free &lt;scp&gt;RNA&lt;/scp&gt;"
2024
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany
European Journal of Cancer·2024· 3 citedOpen Access
Corrigendum to “Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)”
ESMO Open·2024Open Access
The WERA Cancer Center Matrix: Strategic Management of Patient Access to Precision Oncology in a Large and Mostly Rural Area of Germany
2024Open Access
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
Journal of Clinical Oncology·2024· 47 citedOpen Access
Alternating application of gemcitabine/<i>nab</i>-paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): First results from the randomized phase 2 ALPACA study from the German AIO study group (AIO-PAK-0114).
Journal of Clinical Oncology·2024· 2 cited
Minimally invasive determination of PDAC subtype and therapy-induced subtype switch by means of circulating cell-free RNA
2024· 1 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Martin Wilhelm(13), Hermann Einsele(9), Andreas Neubauer(9), Hubert Serve(8), Carsten Müller‐Tidow(8), Christian Thiede(8), Wolfgang E. Berdel(8), Gerhard Ehninger(8), Christoph Röllig(7), Richard Noppeney(7), Claudia D. Baldus(7), Alwin Krämer(7), Stefan W. Krause(7), Markus Schaich(7), Thomas Herrmann(7), Volker Heinemann(6), Kerstin Schäfer‐Eckart(6), Mathias Hänel(6), Ulrich Kaiser(6), Martin Bornhäuser(6)